Pneumococcal Immunogenicity in Nephrotic Syndrome Study

Infections occurring in individuals with glomerular disease are preventable contributors to excess healthcare utilization, morbidity, and mortality, and are the leading cause of death in children with glomerular disease. Vaccination is a powerful and cost-effective method to attenuate infectious burden, and clinical guidelines recommend that patients with glomerular disease receive 23-valent pneumococcal (PPSV23) vaccine. The main objective of the study is to determine functional PPSV23 immunogenicity in a prospectively collected multicenter cohort of children with idiopathic nephrotic syndrome using measurements of anti-pneumococcal and opsonophagocytic antibody titers prior to, and 1, 3 and 12 months following PPSV23 vaccination.